WallStSmart

Jabil Circuit Inc (JBL)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Jabil Circuit Inc generates 963% more annual revenue ($32.67B vs $3.07B). WST leads profitability with a 16.1% profit margin vs 2.5%. JBL appears more attractively valued with a PEG of 0.82. JBL earns a higher WallStSmart Score of 70/100 (B).

JBL

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 6.0Value: 9.3Quality: 4.8
Piotroski: 3/9Altman Z: 2.35

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

JBLUndervalued (+24.9%)

Margin of Safety

+24.9%

Fair Value

$347.72

Current Price

$283.24

$64.48 discount

UndervaluedFair: $347.72Overvalued
WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$247.02

$178.03 premium

UndervaluedFair: $68.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JBL4 strengths · Avg: 9.0/10
Return on EquityProfitability
59.7%10/10

Every $100 of equity generates 60 in profit

EPS GrowthGrowth
96.2%10/10

Earnings expanding 96.2% YoY

PEG RatioValuation
0.828/10

Growing faster than its price suggests

Revenue GrowthGrowth
23.1%8/10

Revenue surging 23.1% year-over-year

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

JBL4 concerns · Avg: 3.3/10
P/E RatioValuation
37.3x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
2.5%3/10

2.5% margin — thin

Operating MarginProfitability
4.7%3/10

Operating margin of 4.7%

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : JBL

The strongest argument for JBL centers on Return on Equity, EPS Growth, PEG Ratio. Revenue growth of 23.1% demonstrates continued momentum. PEG of 0.82 suggests the stock is reasonably priced for its growth.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : JBL

The primary concerns for JBL are P/E Ratio, Profit Margin, Operating Margin. Thin 2.5% margins leave little buffer for downturns.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

JBL profiles as a growth stock while WST is a mature play — different risk/reward profiles.

JBL carries more volatility with a beta of 1.18 — expect wider price swings.

JBL is growing revenue faster at 23.1% — sustainability is the question.

JBL generates stronger free cash flow (316M), providing more financial flexibility.

Bottom Line

JBL scores higher overall (70/100 vs 55/100) and 23.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Jabil Circuit Inc

TECHNOLOGY · ELECTRONIC COMPONENTS · USA

Jabil Inc. provides global manufacturing solutions and services. The company is headquartered in Saint Petersburg, Florida.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?